Metastatic castration-resistant prostate cancer has poor survival outcomes. New prognostic gene panels are being used in developing ways to interrogate the likely natural history of an individual's disease. Biomarker innovations to calculate tumour burden also hold promise for the future, but there is still some way to go to validate and stratify their use.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.